Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04952610 · ClinicalTrials.gov registry record · Phase 3
Etripamil Nasal Spray in Patients With Paroxysmal Supraventricular Tachycardia
A Phase 3 study, sponsored by Milestone Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 130
- Enrollment target
NCT04952610: Completed Phase 3 study, sponsored by Milestone Pharmaceuticals.
NCT04952610 is a Phase 3 study that has completed, run by Milestone Pharmaceuticals. The registered enrollment target is 130 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (83% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04952610, a Phase 3 study, has completed, sponsored by Milestone Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 130 participants
- Enrollment target
Study Summary
This Open Label Extension study will enable eligible patients with Paroxysmal Supraventricular Tachycardia (PSVT) who have previously participated in a Milestone Pharmaceuticals clinical trial of etripamil NS for PSVT, to access continued treatment with etripamil NS, Patients who experienced any significant safety issues during participation period in a previous clinical trial of etripamil NS, as per Investigator's assessment , are excluded. This study will be conducted by Investigators who previously participated in a Milestone Pharmaceuticals clinical trial and are trained on the use of etripamil NS.
Interventions
- DRUG Etripamil NS 70 mg
- DEVICE Aptar Pharma Nasal Spray Bidose System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Start Date | 2021-12-13 |
| Est. Completion | 2026-04-10 |
| Phase | Phase 3 |
What the finished NCT04952610 record still lists
NCT04952610 is an interventional study that assigns participants to a tested intervention. The registered 130 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (83% lower).
The record links to 0 conditions, and to 2 interventions - of which Etripamil NS 70 mg is the first listed.
NCT04952610 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04952610 about?
NCT04952610 is a clinical study titled "Etripamil Nasal Spray in Patients With Paroxysmal Supraventricular Tachycardia". This Open Label Extension study will enable eligible patients with Paroxysmal Supraventricular Tachycardia (PSVT) who have previously participated in a Milestone Pharmaceuticals clinical trial of etripamil NS for PSVT, to access continued treatment with etripamil NS, Patients who experienced any sig...
What is the current status of trial NCT04952610?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 130 participants. The study started on 2021-12-13. Estimated completion is 2026-04-10.
What interventions are being tested in trial NCT04952610?
The interventions under investigation include: Etripamil NS 70 mg (DRUG), Aptar Pharma Nasal Spray Bidose System (DEVICE).
Who is sponsoring clinical trial NCT04952610?
This trial is sponsored by Milestone Pharmaceuticals, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04952610's enrollment target sits among peer trials
130 1594th of 2000 higher than 404 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01492036 · 130 participants
Long-Term Follow-Up of Recipient of Gene Transfer Research
- NCT01631617 · 130 participants · Phase 2
Effects of Treatments on Atopic Dermatitis
- NCT02368041 · 130 participants
Utility of Thenar Near Infrared Spectroscopy (NIRS) in Pediatric Patients With Heart Failure
- NCT02604277 · 130 participants · NA
Suicidal Behavior in Patients Diagnosed With Bipolar Disorder
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI